Hunter Perkins Capital Management LLC Buys Shares of 30,898 Zoetis Inc. $ZTS

Hunter Perkins Capital Management LLC purchased a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 30,898 shares of the company’s stock, valued at approximately $3,888,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC boosted its stake in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates acquired a new position in Zoetis in the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC purchased a new position in Zoetis in the 4th quarter valued at about $32,000. Finally, Financial Consulate Inc. purchased a new position in Zoetis in the 3rd quarter valued at about $39,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZTS shares. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Down 2.7%

ZTS opened at $113.48 on Friday. Zoetis Inc. has a 12 month low of $113.29 and a 12 month high of $172.23. The business has a 50-day moving average of $123.39 and a two-hundred day moving average of $129.17. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a market capitalization of $47.90 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 1.73 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the firm posted $1.40 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.